contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


pharma-equity-group-peg-signs-letter-of-intent-loi-to-acquire-medtech-company-otiom

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Equity Research Analyst

Philip Coombes

Pharma Equity Group udvikler nye lægemidler til lokalbehandling af alvorlige og livstruende betændelsessygdomme hvor der i dag ikke findes en tilstrækkelig behandling. Selskabet benytter sig af repositionering af eksisterende lægemidler og fører lægemiddelkandidater frem til et klinisk fase III stadie hvorefter det overgives til en strategisk partner, der vil færdigudvikle produkterne og bringe dem på markedet, enten selvstændigt eller i samarbejde med selskabet.

Pharma Equity Group

Pharma Equity Group (PEG) has taken the first tangible step in executing its diversification strategy announced in May 2025 by signing a Letter of Intent (LOI) to acquire Otiom A/S, a Danish MedTech company specializing in IoT-based localization technology for people with dementia. The transaction marks PEG’s initial expansion beyond pharmaceuticals into commercial-stage MedTech and aligns with CEO Christian Tange’s (new CEO from 1 April 2025) ambition to become a Nordic life sciences consolidator.

Pharma Equity Group (PEG) has taken the first tangible step in executing its diversification strategy announced in May 2025 by signing a Letter of Intent (LOI) to acquire Otiom A/S, a Danish MedTech company specializing in IoT-based localization technology for people with dementia. The transaction marks PEG&#x2019;s initial expansion beyond pharmaceuticals into commercial-stage MedTech and aligns with CEO Christian Tange&#x2019;s (new CEO from 1 April 2025) ambition to become a Nordic life sciences consolidator.
The agreement values Otiom at an enterprise value of approximately DKK 15 million. The structure of the deal is primarily a share-for-share exchange, expected to represent around 10% dilution to PEG&#x2019;s current share capital in the event of a full acquisition. Importantly, PEG will assume Otiom without any legacy debt, and the existing management team will remain in place. The parties have initiated an exclusive due diligence process and expect to sign a final agreement by the end of January 2026.
Otiom currently operates in 24 countries with over 9,700 units deployed and a network of 13 distributors across Europe, with particularly strong growth in the DACHNL region. The company generates roughly DKK 8 million in annual revenue and operates close to break-even, supported by recurring demand for its dementia safety technology. PEG&#x2019;s management expects the acquisition to have a positive impact on group cash flow and EBITDA from 2026 onwards.
Strategically, the Otiom deal represents execution of the strategy shift by adding a commercial-stage MedTech business with a shorter path to profitability. The acquisition will broaden PEG&#x2019;s exposure beyond drug development through Reponex Pharmaceuticals and may generate cash flow in the near-to-medium term to support the development of Reponex Pharmaceuticals&apos; pipeline assets; however, no financials are currently disclosed, so this remains speculation.&#xa0;
Disclaimer: HC Andersen Capital receives payment from Pharma Equity Group for a digitalIR/corporate visibility subscription agreement. / Philip Coombes 13:31 10/12-2025

HC Andersen Capital

Pharma Equity Group (PEG) - Signs Letter of Intent (LOI) to acquire MedTech company Otiom